Show simple item record

dc.contributor.authorBurza, Sakib
dc.contributor.authorSinha, Prabhat Kumar
dc.contributor.authorMahajan, Raman
dc.contributor.authorSanz, Marta González
dc.contributor.authorLima, María Angeles
dc.contributor.authorMitra, Gaurab
dc.contributor.authorVerma, Neena
dc.contributor.authorDas, Pradeep
dc.date.accessioned2014-01-20T21:28:35Z
dc.date.available2014-01-20T21:28:35Z
dc.date.issued2014-01
dc.identifier.citationPost Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India. 2014, 8 (1):e2611 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735
dc.identifier.pmid24392171
dc.identifier.doi10.1371/journal.pntd.0002611
dc.identifier.urihttp://hdl.handle.net/10144/311612
dc.description.abstractThe skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India-an area highly endemic for Leishmania donovani-in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL.
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.subjectKala Azar/Visceral Leishmaniasisen_GB
dc.titlePost Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, Indiaen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB
refterms.dateFOA2019-03-04T10:58:34Z
html.description.abstractThe skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India-an area highly endemic for Leishmania donovani-in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL.


Files in this item

Thumbnail
Name:
Burza et al-2014-Post Kala Azar ...
Size:
286.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record